Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

The date of first ofatumumab prescription claim or other DMT of interest was defined as the index date. No post-index requirements were imposed. Patients were linked to IQVIA's open source medical claims databases (Dx) to obtain patient clinical characteristics. The initial data were extracted in October 2020. The data and results were refreshed in April 2021 and July 2021 to allow for assessment of changes in characteristics at 6 and 9 months post-launch.